Background: On the basis of encouraging preclinical data, we investigated the combination of the 2 agents recombinant interferon-alpha 2b (IFN-alpha) and recombinant interleukin-2 (rIL-2) in the treatment of patients with metastatic renal cell carcinoma in the hope of finding evidence of an increase in therapeutic efficacy, with an acceptable toxicity profile in comparison to the single substances. Patients and Methods: In a multicenter phase II study, 23 patients with metastatic renal cell cancer were treated with a combination of rIL-2 (Proleukin®, EuroCetus), administered by continuous infusion at a dose of 18 Mio IU/m2/d on days 1-5 and 8-12 and IFN-alpha (Intron-A®, Schering-Plough) at 6 Mio IU/m2/d on days 1, 3, 5, 8,10 and 12. After a rest period of 2 weeks the treatment was repeated. Results: Five complete remissions (CRs) and 2 partial remissions (PRs) were observed, with a total response rate of 30%. All CRs occurred in patients with lung metastases. Durable CRs were observed in 2 patients, without maintenance therapy for now 42+ and 49 + months. Toxicity was usually manageable on a routine medical ward. Grade IV hypotension was observed in 2 patients and there was 1 case of colonic perforation and 1 case of fatal pulmonary embolism. Conclusions: In the present phase II study, combination treatment with rIL-2 + IFN-alpha was found to be an active although toxic regimen.

Keywords:
Interferon-alpha, Interleukin-2, Renal cell carcinoma
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.